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Abstract: Nuclear Magnetic Resonance (NMR) spectroscopy is a quantitative analytical tool commonly
utilized for metabolomics analysis. Quantitative NMR (qNMR) is a field of NMR spectroscopy
dedicated to the measurement of analytes through signal intensity and its linear relationship with
analyte concentration. Metabolomics-based NMR exploits this quantitative relationship to identify
and measure biomarkers within complex biological samples such as serum, plasma, and urine.
In this review of quantitative NMR-based metabolomics, the advancements and limitations of
current techniques for metabolite quantification will be evaluated as well as the applications of
qNMR in biomedical metabolomics. While qNMR is limited by sensitivity and dynamic range,
the simple method development, minimal sample derivatization, and the simultaneous qualitative
and quantitative information provide a unique landscape for biomedical metabolomics, which is not
available to other techniques. Furthermore, the non-destructive nature of NMR-based metabolomics
allows for multidimensional analysis of biomarkers that facilitates unambiguous assignment and
quantification of metabolites in complex biofluids.
Keywords: quantitative NMR; qNMR; metabolomics; multidimensional NMR; biomarkers
1. Introduction
Nuclear magnetic resonance (NMR) spectroscopy is an analytical technique routinely used for
biomedical metabolomics. NMR has emerged as a valuable application because of its non-invasive,
non-destructive, highly reproducible, and quantitative capabilities [1]. NMR can produce qualitative
measurements for both known and unknown compounds with little sample preparation [2]. This simple
sample preparation allows for minimal alterations to biomedical samples prior to analysis, avoiding bias
and biologically irrelevant perturbations [2]. Conversely, other analytical techniques require moderate to
extensive sample preparation, chemical derivatization, and time-consuming calibrations to characterize
metabolite concentrations. Furthermore, since NMR is a non-destructive technique, a single sample is
routinely used to acquire multiple one-dimensional and multidimensional experiments for structural
elucidation and metabolite identification. In this regard, NMR may avoid potential sources of
inconsistencies or contradictions that may arise from the intrinsic biological variance in replicate samples.
Despite these strengths, NMR does encounter several limitations in the analysis of complex biofluids
that include lower relative sensitivity and a limited dynamic range. Nevertheless, NMR methodologies
continue to evolve and to improve and, accordingly, the application of NMR for the identification and
quantification of metabolites has increased dramatically over the past 20 years (Figure 1).
Molecules 2020, 25, 5128; doi:10.3390/molecules25215128 www.mdpi.com/journal/molecules
Molecules 2020, 25, 5128 2 of 33
Molecules 2020, 25, x 2 of 32 
Molecules 2020, 25, x; doi: www.mdpi.com/journal/molecules 
 
Figure 1. Summary of NMR metabolomic publications (blue) and quantitative NMR metabolomic 
publications (red) in PubMed. 
NMR spectroscopy is inherently quantitative, where signal intensity is directly proportional to 
the number or count of each individual nuclei (i.e., 1H, 13C, 15N, etc.) present in a sample [3]. This 
feature makes NMR a natural companion to metabolomics since an overarching goal of the field is to 
determine the concentration of each detectable metabolite in a biological sample. Quantitative NMR 
(qNMR) is a specialized subdiscipline within the NMR field that focuses on the highly accurate and 
reproducible measurements of molecular concentrations [4,5]. qNMR is commonly employed for the 
analysis of compounds within complex mixtures. Specifically, qNMR has been extensively used for 
decades within the pharmaceutical industry to quantify active drugs from a variety of complex 
matrices (e.g., body fluids, drug formulation, natural product extracts, etc.) [6–8]. Thus, qNMR is also 
a useful method for the determination of metabolite concentrations and, accordingly, has seen 
expanded utilization in metabolomics [9]. A schematic overview of the application of qNMR to 
metabolomics is shown in Figure 2. The qNMR protocol consists of five steps corresponding to: (1) a 
simplified sample preparation, (2) selection of reference standards, (3) analyte detection, (4) 
metabolite deconvolution, and (5) metabolite quantification. The qNMR protocol is highly flexible 
and allows for the inclusion of multidimensional NMR experiments and the integration of other 
analytical techniques as appropriate. 
There are two basic methods of metabolite quantification by qNMR: relative quantification and 
absolute quantification [3]. Relative quantification involves the measurement of molar concentrations 
relative to control samples. This quantification method is commonly used in biomedical 
metabolomics as a tool to distinguish disease state models from healthy control groups, among other 
types of comparisons. In NMR-based metabolomics, a relative quantification is commonly achieved 
through multivariate and univariate statistical analyses of binned NMR spectral data [10]. The 
resulting statistical models are then utilized to distinguish between the groups and to identify 
metabolites that vary between the healthy and disease groups. For relative quantification, especially 
multivariate model analysis, metabolite changes are not independently assessed, but are correlated 
with other metabolites. Conversely, absolute quantification is the direct measurement of individual 
compound concentrations independent of all other compounds in the biological sample. Absolute 
quantification is commonly facilitated by the use of internal standards and metabolite deconvolution 
[3]. Metabolite deconvolution is achieved in one-dimensional (1D) NMR metabolomics either 
computationally (i.e., peak fitting) (Section 2.1.6) [11] or experimentally by separating metabolites 
with analytical methods such as chromatography (Section 2.1.5) [12] or NMR pulse sequences to 
select metabolites of interest (Section 2.1.3). Deconvolution can also be achieved by multidimensional 
NMR approaches, in which metabolites are separated along a second dimension by means of 
through-bond (i.e., HSQC) or through-space (i.e., NOE) correlations (Section 3.1). 
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N R spectroscopy is inherently quantitative, where signal intensity is directly proportional
to the number or count of each individual nuclei (i.e., 1H, 13C, 15N, etc.) present in a sample [3].
This feature makes NMR a natural companion to metabolomics since an overarching goal of the field
is to determine the concentration of each detectable metabolite in a biological sample. Quantitative
NMR (qNMR) is a specialized subdiscipline within the NMR field that focuses on the highly accurate
and reproducible measurements of molecular concentrations [4,5]. qNMR is commonly employed for
the analysis of compounds within complex mixtures. Specifically, qNMR has been extensively used
for decades within the pharmaceutical industry to quantify active drugs from a variety of co plex
atrices (e.g., body fluids, drug for ulation, natural product extracts, etc.) [6–8]. Thus, qNMR is also a
useful method for the determination of metabolite concentrations and, accordingly, has seen expanded
utilization in metabolomics [9]. A schematic overview of the application of qNMR to metabolomics is
shown in Figure 2. The qNMR protocol consists of five steps corresponding to: (1) a simplified sample
preparation, (2) selection of reference standards, (3) analyte detection, (4) metabolite deconvolution,
and (5) metabolite quantification. The qNMR protocol is highly flexible and allows for the inclusion of
multidimensional NMR experiments and the integration of other analytical techniques as appropriate.
There are two basic methods of metabolite quantification by qNMR: relative quantification and
absolute quantification [3]. Relative quantification involves the measurement of molar concentrations
relative to control samples. This quantification method is commonly used in bio edical metabolomics
as a tool to distinguish disease state models from healthy control groups, among other types of
comparisons. In NMR-based metabolomics, a relative quantification is commonly achieved through
multivariate and univariate statistical analyses of binned NMR spectral data [10]. The resulting
statistical models are then utilized to distinguish between the groups and to identify metabolites that
vary between the healthy and disease groups. For relative quantification, especially multivariate model
analysis, metabolite changes are not independently assessed, but are correlated with other metabolites.
Conversely, absolute quantification is the direct measurement of individual compound concentrations
independent of all other compounds in the biological sample. Absolute quantification is commonly
facilitated by the use of internal standards and metabolite deconvolution [3]. Metabolite deconvolution
is achieved in one-dimensional (1D) NMR metabolomics either computationally (i.e., peak fitting)
(Section 2.1.6) [11] or experimentally by separating metabolites with analytical methods such as
chromatography (Section 2.1.5) [12] or NMR pulse sequences to select metabolites of interest
(Section 2.1.3). Deconvolution can also be achieved by multidimensional NMR approaches, in which
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metabolites are separated along a second dimension by means of through-bond (i.e., HSQC) or
through-space (i.e., NOE) correlations (Section 3.1).Molecules 2020, 25, x 3 of 32 
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Figure 2. Overview of NMR-based metabolite quantification in biomedical metabolomics. Step 1: 
Sample preparation through deproteinization and/or centrifugation of biofluids. Step 2: Selection of 
reference standard(s) for determination of unknown metabolite concentration. Step 3: Detection of 
analyte signal through NMR spectroscopy. Step 4: Metabolite deconvolution by which data is filtered 
for significant biomarkers of interest. Deconvolution can be achieved through computational methods 
after data collection and/or experimental design prior to data collection. Step 5: Metabolites are 
quantified by comparison of known metabolite concentration to unknown analytes. The figure was 
generated using free medical images from Servier Medical Art (https:/smart.servier.com/) under the 
Creative Commons License Attribution 3.0 Unported (CC BY 3.0). 
Advancements in high-field magnets, cryoprobe technology, and pulse sequence design have 
continued to push the limits of metabolite quantification below traditional µM concentrations [13]. 
More importantly, qNMR has been extensively utilized in pharmaceutical studies, where the 
chemical purity of organic compounds can be estimated with an accuracy and precision of ±1% and 
an uncertainty less than 0.1% [7]. Furthermore, the implementation of new internal standards and 
software-assisted metabolite deconvolution techniques has enabled an accurate and broader 
coverage of metabolites within complex biomedical samples [1,14]. The inclusion of 
multidimensional NMR, alternative NMR nuclei (e.g., 13C, 15N, and 31P), and solid state NMR has 
further expanded the utility of qNMR to metabolomics studies [15–17]. Additionally, qNMR has 
found utility in combined analytical techniques, such as HPLC–NMR and NMR–MS [18–21]. Notably, 
a broader identification and quantification of the metabolome is achievable by combining multiple 
analytical techniques that are beyond the capabilities of each individual method. Overall, recent 
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Advancements in high-field magnets, cryoprobe technology, and pulse sequence design have
continued to push the limits of metabolite quantification below traditional µM concentrations [13].
More importantly, qNMR has been extensively utilized in pharmaceutical studies, where the chemical
purity of organic compounds can be estimated with an accuracy and precision of ±1% and an
uncertainty less than 0.1% [7]. Furthermore, the implementation of new internal standards and
software-assisted metabolite deconvolution techniques has enabled an accurate and broader coverage
of metabolites within complex biomedical samples [1,14]. The inclusion of multidimensional NMR,
alternative NMR nuclei (e.g., 13C, 15N, and 31P), and solid state NMR has further expanded the
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utility of qNMR to metabolomics studies [15–17]. Additionally, qNMR has found utility in combined
analytical techniques, such as HPLC–NMR and NMR–MS [18–21]. Notably, a broader identification
and quantification of the metabolome is achievable by combining multiple analytical techniques that
are beyond the capabilities of each individual method. Overall, recent advancements in qNMR
technology have significantly improved metabolite quantification, while beneficially impacting
metabolomics. In this review, the current status and applications of qNMR, the recent advancements in
multidimensional qNMR, and outstanding qNMR challenges and limitations will be discussed.
2. Metabolite Quantification in 1D NMR Metabolomics
One-dimensional NMR metabolomics has commonly been divided into two distinct yet
complimentary camps: untargeted metabolomics or fingerprinting, and targeted or qNMR. Untargeted
metabolomics comprises a simple methodology in which the sample is minimally altered or changed
prior to analysis. The chemical composition of an entire biological sample is then characterized
or ‘fingerprinted’ in a single experiment. Untargeted metabolomics is thus useful for categorizing
biomedical samples, especially disease state identification. Numerous studies have evaluated disease
states from global metabolomic changes by comparing disease state models to healthy controls [1,22–24].
A predominant feature of the success of high-throughput untargeted metabolomics is the relative
quantification of metabolites. Untargeted metabolomics can be readily transformed into qNMR by the
addition of internal standards with known concentrations. Simply, the concentration of the internal
standard can then be used to quantify the metabolites. Special attention must be paid to the choice of
the internal standard(s) used for a specific analysis or sample type.
For 1D qNMR, a number of issues complicate the identification and quantification of metabolites
in complex biological solutions. Specifically, peak or spectral overlap, a lack of a universally reliable
internal standard, sample size, and the limited dynamic range of NMR may make it difficult to quantify
a specific metabolite. Peak or spectral overlap is a serious issue that challenges the quantification of
NMR spectra. This problem is particularly pronounced for 1D 1H-NMR spectra due to the limited
chemical shift range of metabolites (~10 ppm). A 1H-NMR spectrum provides a single snapshot of all
the detectable compounds (>1 to 5 µM) present in the solution. While this results in a unique fingerprint
for every sample, it also means that metabolites with similar chemical structure will appear close
together in the spectrum, leading to spectral overlap [25,26]. This situation is further exacerbated by
the complexity of the biological samples. The more metabolites that are present in the sample, the more
likely spectral overlap will occur. Furthermore, large variations in metabolite concentrations (i.e., µM
to mM) will also contribute to the difficulty in detecting a specific metabolite. Simply, an NMR peak
from a high concentration metabolite (mM) is likely to mask or obscure a peak for a low concentration
metabolite (µM).
Peak overlap due to similar chemical structures is particularly difficult when metabolite
quantification of a metabolic pathway is desired. For example, the glycolysis pathway consists
of modifications and additions to the core glucose molecule. While each step of glycolysis yields a
unique product, there are several repeating chemical scaffolds that result in a significant chemical
shift overlap in the 3.2 to 4.5 ppm region of a 1D 1H-NMR spectrum. It would be difficult, if not
impossible, to quantify a particular metabolite in the glycolysis pathway without deconvolution
techniques. Deconvolution of the NMR spectra is a means of removing or isolating metabolites
of interest from other peaks that may interfere with the analysis. The deconvolution of qNMR
spectra has been accomplished by the application of: 1D NMR pulse sequences (Section 2.1.3),
chromatography (Section 2.1.5), computational analysis after data collection (Section 2.1.6), alternative
nuclei (Section 2.2.1), two-dimensional (2D) NMR (Section 3), or by chemical additives prior to or
during data collection.
One approach to simplify an NMR spectrum would be to completely remove the carbohydrate
background by removing all of the carbohydrates from the sample. This was accomplished by
selectively oxidizing carbohydrates with sodium periodate followed by removal of the product with
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hydrazide beads [27]. Other metabolites were not affected by the oxidative removal of the carbohydrates
and the resulting NMR spectra were greatly simplified. A similar “Add to Subtract” approach removes
the glucose signal by adding a concentrated drop of glucose to a sample post initial data collection,
with subsequent collection of a second spectrum. A glucose-free spectrum is created by subtracting the
two spectra, which reveals the hidden metabolites lost behind the glucose signal [28]. Another approach
of removing metabolites from an NMR spectrum has been accomplished by using nanoparticles to bind
specific metabolites [29] or with NMR shift reagents (e.g., gadolinium, Gd3+) [30,31] that broaden NMR
signals due to T2 relaxation. Enzymatic activity has also been utilized to remove signal interference
(e.g., removal of urea from urine with urease) [32,33]. An alternative approach is to chemically
modify select chemical classes to introduce a distinct 15N or 13C chemical shift to circumvent the
spectral overlap problem. For example, carboxyl and carbonyl groups may be selectively tagged with
15N-cholamine [34] or N-(2-15N-aminooxyethyl)-N,N-dimethyl-1-dodecylammonium [35]. Of course,
in all cases, the sample has been significantly manipulated, it is no longer possible to quantify the
removed metabolites, and the approach is limited to the chemical removal or modification of a
few select chemical classes or compounds. The effect may not be uniform or reproducible across
samples or metabolites, and the impact on other metabolites may be difficult to ascertain. Accordingly,
the chemical removal or modification of metabolites is not commonly employed by high-throughput
NMR-based metabolomics.
2.1. Techniques in 1D Metabolite Quantification by NMR
2.1.1. Sample Storage and Preparation for Metabolomics Analysis
The preservation of the metabolomic signature from biofluid samples (i.e., serum, blood, urine,
cerebral spinal fluid, and saliva) is an utmost priority. The object of any metabolomics study is to
ensure that the analysis accurately represents the intact metabolome of the collected biofluid and
avoids any unintended bias. Ideally, the biofluid samples should be analyzed by NMR shortly
after collection. If this is not possible or practical, the biofluids are typically stored at −80 ◦C until
analyzed [36]. Multiple freeze–thaw steps should be avoided [37,38]. The preferred pre-analytical
procedure for metabolomics analysis involves minimal sample interaction. The simplest sample
preparation protocol requires only centrifugation at 4 ◦C to remove any debris followed by the addition
of a deuterated lock solvent (e.g., D2O) for NMR data collection [39]. Commonly, a deuterated buffer is
used to achieve a constant physiological pH across the entire sample set to minimize chemical shift
variation between samples [40]. Another simple technique for biofluid preparation requires treatment
with methanol or methanol:chloroform to precipitate biomolecules and prevent further enzymatic
activity [41,42]. Ultrafiltration has also been utilized, but may result in significant metabolite loss
due to macromolecule binding, and should be used with caution when accurate quantification is
desired [42,43]. Tissue samples are also commonly analyzed by solution state NMR, but must be
homogenized prior to metabolite extraction [44]. Prior to sample storage, the effective concentration
of biofluid samples may be improved by drying the sample and then, reconstituting in a phosphate
buffer to the desired sample volume [44]. This is particularly useful when a limited sample is
available for NMR analysis, but it does require extra preparation time and may perturb the sample
leading to erroneous quantification. In general, the goal of pre-analytical metabolomic extraction
is efficiency and consistency. Many protocols require keeping the samples on ice throughout the
procedure to avoid sample degradation. Several studies have evaluated the delay time between sample
collection, storage, and experimental analysis, as well as the effects of temperature on metabolite
degradation. For a comprehensive review of pre-analytical techniques, please see the recent reviews
by Bi et al. 2020 [45], Haid et al. 2018 [46], Wang et al. 2018 [47], and Bervoets et al. 2015 [48].
Following pre-analytical preparation, NMR sample preparation requires the addition of phosphate
buffer to maintain a physiological pH (pH 7.0–7.4) [40]. Furthermore, maintaining pH levels in sample
preparation is beneficial for metabolite identification and quantification against library standards. For a
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detailed review of high-throughput metabolomics pre-processing protocols for biofluids, please see
recent reviews by Vignoli et al. 2019 [40] and Beckonert et al. 2007 [2], for lipid profiling see Barbosa et al.
2108 [49], for tissue extraction see Bhinderwala et al. 2019 [44], and for solid state metabolomics
protocols see Tilgner et al. 2019 [50].
2.1.2. Reference Standards for Absolute Quantification
Reference standards are a critical component of qNMR since they are the concentration calibrant
for metabolite quantification. There are three common techniques for creating a reference standard in
qNMR: (1) an internal reference consisting of a compound directly added to the sample, (2) an external
reference consisting of a compound physically separated from the sample, and (3) the Electronic
REference To access In vivo Concentrations (ERETIC) method [51]. An internal standard relies on
consistent peak heights and peak shapes for all resonances within an NMR spectrum, while an external
standard relies on consistent instrument and environmental conditions for all NMR spectra in a
dataset [3]. Internal standards have long been used in qNMR techniques due to their high level of
accuracy and precision [52,53]. Compounds commonly used as an internal reference for NMR-based
biofluid analysis include deuterated trimethylsilylpropanoic acid (TMSP-D4), trimethylsilyl propionate
(TSP-D4), and 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS). These internal standards are extremely
important to metabolite quantification because they provide an identifiable concentration reference
that is isolated from areas of significant spectral overlap. Unfortunately, DSS, TMSP-D4 and TSP-D4
have been observed to bind proteins and other macromolecules found in complex biological samples.
Even the presence of a small amount of a protein may cause peak distortion that would lead to
inaccurate concentration measurements [2,54,55]. DSS, TMSP-D4, and TSP-D4 are also susceptible to
pH changes since they are weak acids [56]. Formic acid and maleic acid have also been utilized as
internal standards and do not bind proteins [2,54,57]. However, formic acid and maleic acid must
be used with caution since these are naturally occurring metabolites (i.e., formate metabolism and
glycolysis) and may be present in some sample types. In these cases, the inclusion of formic acid or
maleic acid may lead to inaccurate metabolite quantification. Octamethylcyclotetrasiloxane (OMS) has
also been used as an internal standard for lipid samples [58]. OMS has a boiling point of 448K compared
to the more volatile TMS (boiling point 301 K) and has been shown to provide better quantification in
chloroform solutions. External standards, on the other hand, eliminate concerns regarding chemical
shift changes or peak distortions resulting from molecular interactions or pH differences, while also
avoiding peak overlap [3,54]. Simply, separate NMR samples are prepared for the external standard
and the biological sample, and NMR spectra are collected under identical experimental parameters and
instrumental conditions. Nevertheless, there are also challenges with external standards. For example,
external standards drift with time and require multiple calibrations over the course of an experiment
to maintain accuracy. Internal and external standards are both routinely used in qNMR. Interestingly,
external standards are commonly used by the pharmaceutical industry to determine drug purity
levels [59,60], but are less common in metabolomics since internal standards are widely utilized.
ERETIC is an alternative option to using a chemical compound as a reference standard. ERETIC
provides an externally calibrated digital signal that creates a reference peak in an NMR spectrum of
a complex biofluid sample [51]. Importantly, the frequency of the ERETIC signal can be set to any
value within the range of the frequency synthesizer. In this regard, the ERETIC reference signal can
avoid peak overlap and can be adjusted, as needed, to appear in any location in the NMR spectrum.
Notably, the ERETIC signal is very stable compared to external chemical standards and only requires
monthly calibrations [51]. In one study, ERETIC2 (an updated version) and the peak deconvolution
software Chenomx were used to generate absolute quantification of metabolites in serum samples [61].
The combined method was defined as software-assisted serum metabolite quantification (SASMeQ).
SASMeQ was able to quantify 37 metabolites in serum. ERETIC has also been successfully employed
by magnetic resonance imaging [62]. In this study, a 3T MRI system utilized ERETIC to determine
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the accurate concentration of brain metabolites. ERETIC was shown to be a valid alternative to the
commonly used internal water referencing approach in single-voxel magnetic resonance spectroscopy.
In a comparative study of the three quantitation methods, all approaches demonstrated a linear
response from 75 to 0.1 mg/mL (1 mg/mL for the internal method) [3]. Conversely, the internal method
yielded a better accuracy (−0.1%) compared to the external (−0.3%) and ERETIC (−0.5%) methods.
Similarly, the internal method demonstrated a better sample to sample precision (0.3%) compared to
the precision of the external (0.7%) and ERETIC (0.6%) methods. Notably, the time-dependent precision
(i.e., weekly repeated measurements) of the internal standard method was better than the sample to
sample precision. Again, the precision of the internal method (0.1%) was better than the precision for
the external (0.3%) or ERETIC (0.3%) methods. Importantly, all three methods were stable for at least a
month. Overall, the three quantitation methods yielded acceptable accuracy and precision (<1%) and
are equally applicable to qNMR. The external standard and ERETIC methods may be preferred for
samples with a large range of concentrations while also avoiding potential protein binding interactions
that may occur with internal standards.
2.1.3. NMR Approaches to Filter Macromolecules for Metabolite Quantification
Biofluids contain a large variety of macromolecules (e.g., proteins, DNA, etc.), which may
result in significant peak overlap with limited potential for metabolite quantification by qNMR.
Pre-analytical procedures such as protein precipitation and ultrafiltration can alleviate overcrowding
and simplify the spectral landscape by removing macromolecules. Elimination of macromolecules
from biofluids, however, removes the potential for the examination of these other profiles by NMR
and multi-omics approaches. Three NMR methods are commonly used to filter macromolecules from
the NMR spectrum for metabolomics analysis: Nuclear Overhauser Effect Spectroscopy (NOESY),
the Carr–Purcell–Meiboom–Gill (CPMG) pulse sequence, and the diffusion-edited approach [40].
One-dimensional 1H NOESY pulse sequence with selective solvent suppression (e.g., H2O) is
the simplest method of metabolite detection, in which all molecules in the sample are observed,
including macromolecules [63]. Accordingly, the 1D 1H NOESY experiment requires a pre-analytical
filtration step, such as methanol extraction or ultrafiltration, to remove lipids and proteins [42,64].
Alternatively, the CPMG spin-echo pulse sequence enables the detection of small molecular weight
molecules within a complex mixture still containing the larger macromolecules. CPMG exploits the
large difference in transverse or spin–spin relaxation (T2 relaxation) times between small molecules
and macromolecules to filter out the NMR signals from proteins and other biomolecules. Notably, the
CPMG produces a 1D 1H-NMR spectrum similar to a NOESY spectrum, which is obtained following
removal of macromolecules by methanol extraction. Nevertheless, the CPMG pulse sequence should
be used with caution since it encounters similar problems to ultrafiltration. Any metabolite bound to a
protein or other biomolecule will result in a loss of signal and ultimately, an inaccurate quantification.
Metabolites, such as tyrosine, histidine, phenylalanine, and tryptophan, that bind to proteins in
complex biofluids, have shown significant peak broadening due to a decrease in T2 relaxation [65].
The bound metabolite effectively adopts the T2 value of the protein and the CPMG effectively filters
the protein-bound metabolite. The resulting decrease in peak intensity or peak area for the remaining
free-metabolite will result in an underestimation of the metabolite’s true concentration.
The diffusion-edited pulse sequence also allows for the selective observation of macromolecules
in an NMR spectrum [49]. The Longitudinal Eddy-Current Delay (LED) pulse sequence exploits the
significant difference in the molecular weight-dependent translational diffusion coefficient between
small molecules and macromolecules (Figure 3A) [66,67]. The LED approach produces two distinct
spectra. The first spectrum is collected with a low diffusion gradient and, thus, all metabolites and
macromolecules are equally represented (Figure 3A, panel a). The second spectrum is acquired with a
high diffusion gradient, which results in the removal of metabolites with small diffusion coefficients
while leaving macromolecule signals unaffected (Figure 3A, panel b). A diffusion-edited spectrum is
produced by subtracting the high diffusion spectrum from the low diffusion spectrum, which results in
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a spectrum containing only small molecule metabolite NMR signals (Figure 3A, panel c). The diffusion
edited approach has been successfully employed for the comprehensive analysis of metabolites or for
obtaining lipid profiles for a number of diseases such as lupus nephritis [68] and acute myocardial
infraction [69]. A comparative analysis of NOESY, CPMG, and LED showed that LED detected more
metabolites then CPMG. The LED results were similar to results obtained with ultrafiltration sample
preparation and NOESY pulse sequence (Figure 3B) [64].
In addition to NMR filtration by size, the selective total correlation spectroscopy (TOCSY)
experiment obtains a 1D 1H-NMR spectrum of a single, preselected metabolite from a complex mixture.
The selective TOCSY uses a shaped 180◦ pulse to excite a single resonance to observe the entire
metabolite’s spin system that evolves during the TOCSY spin-lock. The process is repeated for each
additional metabolite by the selective excitation of a different NMR peak. As long as the peak chosen
for selective excitation does not overlap with other peaks in the NMR spectrum, only a single metabolite
will be observed in the resulting TOCSY spectrum. Notably, the other resonances in the metabolite’s
spin system may be extensively overlapped in the 1D 1H-NMR spectrum, but will be completely
resolved in the selective TOCSY spectrum. Thus, selective TOCSY is particularly useful when peak
overlap interferes with metabolite detection, as shown in Figure 3C with the detection of hippurate
upon a selective pulse at 7.88 ppm [70]. The quantification of low-level metabolites (~ 10 µM) that are
at concentrations 1000 times below other major components in a complex mixture is now feasible due
to this dramatic spectral simplification [70,71]. It should be noted that the duration of the selective
excitation pulse negatively impacts TOCSY peak intensities, which decrease with longer pulse lengths.
Furthermore, it is difficult to identify numerous isolated NMR peaks for deconvolution of complex
biofluids. Instead, a “semi-selective” TOCSY experiment with shorter excitation pulse lengths will
result in a spectrum comprising multiple chemical species, but with better sensitivity. The semi-selective
TOCSY is a practical alternative for biofluids [71]. Selective TOCSY experiments have also been used to
identify and quantify unknown metabolites in biofluids such as the identification of 4-deoxythreonic
acid in human urine [18]. A TOCSY optimized mixture elucidation (TOOMIXED) tool was developed
to facilitate the identification of known metabolites in complex mixtures [72]. A series of selective
TOCSY experiments are acquired per selective frequency by varying the TOCSY mixing time (τm)
from 10 to 160 ms. TOCSY peak intensities will modulate as a function of τm and create a unique
pattern representative of the metabolite’s molecular structure. In this manner, metabolites may be
identified by comparing the matrix of τm-dependent normalized peak intensities against a library
of known metabolites. A key aspect of the comparison relies on a focused matching based on the
selective excitation frequency. The TOOMIXED application does not offer metabolite quantification
at this time, but it is an impressive step forward for the structural elucidation of metabolites within
complex biofluids.
2.1.4. Sample Size and Limit of Detection
Sample volume requirements and limit of detection are also challenges in the application of qNMR
to metabolomics. qNMR is limited to identifying the most abundant metabolites in a sample with a
limit of detection of approximately ≥3 µM [7]. qNMR also requires a relatively high sample volume of
~500 µL. The intrinsically low sensitivity of qNMR is a result of the narrow energy difference between
nuclei spin states. One approach to improve the sensitivity of NMR is to pursue higher magnetic
fields; however, this comes with a high price tag and limited accessibility to magnets greater than
18.8T (800 MHz) [73]. Another advancement in NMR sensitivity is the use of cryoprobe technology,
where the NMR probe and its electronics are cooled to near liquid helium temperatures (~20K) to
reduce electronic thermal noise. As a result, a cryoprobe may lead to a three- to four-fold enhancement
in signal to noise. For example, a study examining urinary metabolites associated with drug toxicity
used a direct-detect 13C cryoprobe, which acquired high quality 1D 13C NMR spectra within 30 min
that detected numerous metabolites with sufficient signal-to-noise (Figure 4A) [74]. A companion 2D
1H-13C HSQC spectrum was collected in 4.5 h of naturally abundant (1.1%) 13C-urinary metabolites.
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(b = 10,000 s/mm2, gray). (b) 1H NMR spectrum of blood plasma acquired with a high sensitivity
toward diffusion (b = 10,000 s/mm2). The macromolecule spectra in (a,b) are identical. (c) Difference
spectrum between (a,b). Abbreviations are given for acetate (Ace), acetoacetate (AcA), acetone (Ac),
alanine (Ala), β-hydroxybutyrate (BHB), citrate (Cit), creatinine (Crn), glucose (Glc), isoleucine (Ile),
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L., Quantitative 1H-NMR Spectroscopy of Blood Plasma Metabolites. Analyt cal Chemistry 2003, 75, (9),
2100–2104. C pyright 2003 American Chemical Society. (B) Comparison of the different macromolecular
signal suppression NMR methods: diffusion edited (LED), T2-relaxation edited (CPMG), and the
ultrafiltration (UF) of large molecules NOESY NMR spectrum. (a) The aromatic region, (b) the area
from 3.1 to 2 ppm, and (c) the area from 0.7 to 1.9 ppm. In each area, the peaks detectable by the LED
method are annotated, whereas those only detectable in UF are assigned therein. The most striking
differences between methods include the suppression of macromolecular signals and metabolites lysine,
ornithine, and phenylalanine that are detectable in LED but not in CPMG spectra. Images reproduced
from Bliziotis, N. G.; Engelke, U. F. H.; Aspers, R.; Engel, J.; Deinum, J.; Timmers, H.; Wevers, R.
A.; Kluijtmans, L. A. J., A comparison of high-throughput plasma NMR protocols for comparative
untargeted metabolomics. Metabolomics 2020, 16. (C) Use of semi-s lective total correlation spectroscopy
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NOESY Presat seq ence to achiev water su ression. (b) Low-field expansion of the rat urine proton
NMR spectrum. (c) Selective TOCSY of rat urine with the selective pulse frequency set on the hippurate
7.88 ppm peak (*) and acquired with SP = 10 ms. Reprinted with permission from Sandusky, P.; Raftery,
D., Use of semi-selective TOCSY and the Pearson correlation for the metabonomic analysis of biofluid
mixtures: application to urine. Analytical Chemistry 2005, 77, 7717–7723. Copyright 2005 American
Chemical Society.
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In addition to instrumental changes toward sample sensitivity, advancements in sample
preparation have led to improved metabolite detection and quantification. NMR sensitivity is
directly proportional to sample concentration. However, biofluid samples are often in limited supply,
making every µL of available sample extremely valuable. Thus, reducing the required volumes
for samples would lead to significant improvements in signal-to-noise by increasing the effective
concentration. A popular alternative to improve qNMR sensitivity is to replace traditional 5 mm
NMR probes that require relatively large 500 µL sample volumes with either a 3 mm microprobe (150
µL volume) or a 1.7 mm submicroprobe (30 µL volume). A comparison between 5 and 3 mm NMR
probes yielded an approximate factor of 2 improvement in signal to noise for the 3 mm probe [75].
A similar comparison between 3 and 1.7 mm probes resulted in another 2.4 factor improvement in
signal-to-noise for the 1.7 mm probe [76]. Similar improvements in signal-to-noise can be achieved by
using 3 or 1.7 mm NMR tubes in a standard 5 mm NMR probe. Of course, a further enhancement
in sensitivity is achieved by combining cryoprobe technology with microprobe technology, such as
Bruker’s TCI 1.7 mm MicroCryoProbeTM. This approach is particularly advantageous when working
with limited samples such as biofluids. Thus, detecting metabolites at submicromolar concentrations
is now feasible with micro- or submicro-NMR cryoprobes [77,78].
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acquisition time. ArgSuc—argininosuccinate; Citrl—citrulline; NacCitrl—N-acetyl citrulline; Citr—
citrate; 2-AA—2-aminoadipate; Ala—alanine; Crea—creatine; Crn—creatinine; Tau—taurine; 
THOPC—1,4,5,6-tetrahydro-6-oxo-3-pyridazine carboxylic acid (*tentatively assigned); Tyr—
tyrosine. Reprinted with permission from Keun, H. C.; Beckonert, O.; Griffin, J. L.; Richter, C.; 
Moskau, D.; Lindon, J. C.; Nicholson, J. K., Cryogenic probe 13C-NMR spectroscopy of urine for 
metabonomic studies. Analytical Chemisty 2002, 74, 4588–4593. Copyright 2002 American Chemical 
Society. (B) Hyperpolarization in qNMR. (top) Polarization transfer in signal amplification by 
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(B) H perpolarization in qNMR. (top) Polarization t ansfer in signal amplification by reversi le
exchange (SABRE) schematic. A co-substrate (mtz,1methyl-1,2,3-triazole) is introdu ed f r analyte
hyperpolarization in the low-µM regime. (bottom) depicts NMR response at different analyte
concentrations and calibration curve for drug concentrations dENA and mENA in urine. Error bars
represent standard errors of three repeated measurements. Reproduced from Reile, I.; Eshuis, N.;
Hermkens, N. K. J.; van Weerdenburg, B. J. A.; Feiters, M. C.; Rutjes, F. P. J. T.; Tessari, M., NMR detection
in biofluid extracts at sub-µM concentrations via para-H2 induced hyperpolarization. Analyst 2016,
141, 4001-4005 with permission from The Royal Society of Chemistry. (C) 13C spectrum of normal
human urine (bottom), human urine after derivatization with 1,1′ 13C2 acetic anhydride (middle), and
2D HSQC spectrum of derivatized human urine with increased amino acid sensitivity (top). Image
reproduced from Shanaiah, N.; Desilva, M. A.; Nagana Gowda, G. A.; Raftery, M. A.; Hainline, B. E.;
Raftery, D., Class selection of amino acid metabolites in body fluids using chemical derivatization and
their enhanced 13C-NMR. Proc. Natl. Acad. Sci. USA 2007, 104, 11540–11544. Copyright 2007 National
Academy of Sciences. (D) Stacked plot spectra of 1D 31P spectra for 2 mM solution of AMP (blue),
ADP (red), and ATP (green) at pH 4. Image reprinted with permission from Bhinderwala, F.; Evans, P.;
Jones, K.; Laws, B. R.; Smith, T. G.; Morton, M.; Powers, R., Phosphorus NMR and Its Application to
Metabolomics. Analytical Chemistry 2020, 92, 9536–9545. Copyright 2020 American Chemical Society.
(E) Raw signal intensity resulting from a series of hyperpolarized naturally abundant 15N-NMR
spectra of pyridine, metronidazole, and pyrazine as a function of their concentration. The straight
lines result from linear regression analysis and the square of the sample correlation coefficient—R2
confirms linear behavior. Images reprinted with permission from Fekete, M.; Ahwal, F.; Duckett, S. B.,
Remarkable Levels of N-15 Polarization Delivered through SABRE into Unlabeled Pyridine, Pyrazine,
or Metronidazole Enable Single Scan NMR Quantification at the mM Level. Journal of Physical Chemistry
B 2020, 124, 4573–4580. Copyright 2020 American Chemical Society.
The most common approach available to an NMR spectroscopist to improve sensitivity is signal
averaging, where multiple scans of the same sample are collected in succession and averaged together
to produce the final spectrum. This technique, however, increases signal-to-noise at a rate equivalent to
the square-root of the number of scans and the acquisition time quickly becomes a practical limitation
for high-throughput analysis. This is particularly true for the application of qNMR to metabolomics,
where high throughput is a necessity and the number of samples may reach into the thousands.
Further exasperating the situation is the requirement to wait 5-times the longest T1 value to ensure
complete signal recovery for accurate quantitation of the NMR spectrum. Typical 1H T1 times are in
the range of 1 s, but 13C T1 values can vary significantly, with non-proton bearing carbons having
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very long T1 values on the order of minutes. Thus, qNMR experiments typically strive to minimize
acquisition time and the number of scans.
In addition to the limitation of acquisition time, nuclear spin polarization at room temperature
with typical magnet fields (14 to 18.8 T) remains relatively low (10−6–10−4), which explains the low
sensitivity of 1H and 13C-NMR experiments. A polarization transfer from free-electrons has been
shown to produce a temporary hyperpolarization state, which achieves a dramatic signal enhancement
in the NMR spectrum [79,80]. Parahydrogen-induced polarization (PHIP) of nuclear spins allows for
the enhancement of NMR signals based on the conversion of the correlated state of nuclear spins of
parahydrogen (i.e., H2 or D2) via a catalytic reaction, as shown in Figure 4B. This conversion results
in a four to five order of magnitude enhancement in the NMR signals [81]. Recently, PHIP was
utilized in combination with solid phase extraction to quantify the sub-µM concentrations of drug
compounds in urine (Figure 4B) [82]. Hyperpolarization techniques utilizing 13C, 15N, and 31P nuclei
are discussed in Section 2.2.1. A targeted qNMR approach combined with hyperpolarization may
expand the quantification of dilute compounds in complex mixtures.
2.1.5. Chromatographic Separation Facilitates qNMR
Physical methods of removing spectral overlap are common in qNMR. The combination of
high-performance liquid chromatography (HPLC) with NMR spectroscopy has been utilized to
successfully isolate and quantify metabolites of interest, with particular benefits to pharmaceutical
and drug discovery research [12,83]. Combining NMR and HPLC offers advantages in regions of
high spectral interference as well as access to low-concentration metabolites [84]. One of the largest
hurdles to overcome when combining HPLC and NMR is solvent interference. Methanol–water and
acetonitrile–water are common gradient solvents used to elude compounds from an HPLC column
leading to intense peaks in the NMR spectrum. The use of deuterated solvents, such as D2O and
acetonitrile–D3, may reduce the 1H solvent signals. Of course, the high volume of deuterated solvents
required for HPLC may make this an expensive solution. The saturation of the residual solvent signal
is also complicated by the application of gradient elution. Simply, solvent chemical shifts will change
in concert with the change in the percentage of each solvent used in the gradient. To address this issue,
automatic solvent suppression has been utilized to continually adjust the suppression frequencies as the
solvent composition changes [85]. Even if efficient solvent suppression is achieved, 13C satellite peaks,
which result from the 1.1% natural abundance of 13C in H-C bonds and the high solvent concentrations,
may also cause an issue in the quantification of low abundant compounds due to spectral overlap [85].
One approach to suppress this interference is to use broadband 13C decoupling to collapse the 13C
satellite peaks.
The low sensitivity of NMR may hinder the application of HPLC to qNMR, but technology
advancements continue to decrease the limit of detection in HPLC–NMR techniques [86]. Higher magnetic
field strengths (>18.8T), reduced sample volume by employing micro- or submicroprobes [87]
with microbore HPLC methods [85], and digital filtering and oversampling during NMR data collection [88]
have all contributed to improving detection and quantification in NMR. HPLC–NMR may be used to
detect sensitive nuclei such as 1H, 19F, and 31P [85]. The pharmaceutical industry has routinely utilized
HPLC–NMR to investigate drug metabolism, and to monitor the effects of drugs or drug candidates on
human metabolism, or in animal or in vitro models [85–87]. Notably, HPLC–NMR analysis of human urine
facilitated the identification and quantification of previously unidentifiable low concentration metabolites,
such as 4-deoxythreonic acid [18].
2.1.6. Computational Techniques for Relative and Absolute Metabolite Quantification
The quantification of metabolites is an integral part of NMR metabolomics. One-dimensional
1H NMR spectra of metabolomics samples are characterized by a high level of complexity owing
to the large number of metabolites present in a biofluid. NMR signals from different metabolites
often have similar chemical shifts, which leads to significant spectral overlap. Spectral interference or
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peak overlap makes the manual quantification of metabolites difficult to achieve [89]. To overcome
peak overlap and determine concentration, a reference NMR spectrum needs to be manually adjusted
until peak positions and the sum of the peak intensities match the experimental spectrum. This is an
exceedingly time-consuming and tedious process that is prone to error. As a result, several automated
and semi-automated tools have been developed to assist in the identification and quantification of
metabolites in complex mixtures. Many of these software tools have been developed for targeted
metabolite comparisons by fitting the experimental spectrum against a compound reference library [90].
Many commercial software packages have cultivated large reference libraries of 1D 1H NMR spectra of
known metabolites for comparison and analysis against unknown biomedical samples. For example,
the Chenomx NMR Suite (Chenomx Inc., Edmonton, Canada) is a commercially available software
that offers a large database of common biological and drug metabolite 1H 1D NMR data collected
over a range of magnetic fields (400 to 800 MHz) and pH values (pH 4 to 9). Furthermore, Chenomx
offers supplemental libraries through the open source Human Metabolome Database (HMDB, www.
hmdb.ca) [91]. Bruker also offers a BBIOREFCODE 2 database through their AMIX software package
that contains a spectral database of 800 compounds acquired at 600 MHz. NMR spectra available
in the BBIOREFCODE2 database were acquired at 11 different pH values ranging from pH 3 to 8.
The BBIOREFCODE2 database also contains 2D NMR spectra for select compounds at pH 3, 5,
and 7. Open source compound libraries including the Biological magnetic Resonance Data Bank
(BMRB, www.bmrb.wisc.edu/metabolomics/) [92], the Madison-Qingdao Metabolomics Consortium
Database (MMCD, www.mmcd.nmrfam.wisc.edu) [93], and InterSpin (RIKEN, http://dmar.riken.jp/
interspin/) [94] contain additional NMR spectra for thousands of compounds collected under various
concentration and pH conditions. For example, HMDB houses 1513 compounds with a total of 2862
NMR spectra.
Open source software, Bayesian AuTomated Metabolite Analyzer (BATMAN) [95] and Bayesil [96],
were some of the early applications available to combine reference spectra libraries with automated
metabolite identification and quantification from 1D 1H-NMR spectra. Batman employs a Bayesian
approach to assign metabolites in a 1D 1H spectrum from a target list and a Markov chain Monte Carlo
algorithm to automate relative metabolite quantification [95]. Batman assumes an NMR spectrum of a
complex mixture of metabolites is the linear combination of the individual metabolite’s NMR spectra.
A target spectrum is matched to the experimental spectrum where peak intensities are scaled, and peak
positions are adjusted. On average, Batman is capable of identifying 15 to 20 metabolites, but requires
considerable time to complete an analysis (22 min to match 11 metabolites for the 2.3 to 4.1 ppm
region) [97]. A detailed review of the Batman workflow can be found at Hao et al. 2014 [98]. Bayesil is
comparable to Batman but utilizes probabilistic graphic models to achieve deconvolution of 1D
1H-NMR spectra. The Bayesil web server can identify and quantify more than 60 metabolites in serum,
plasma, and CSF samples in under 10 min. Bayesil, however, is limited by the sample type and the
spectrometer frequency (500 and 600 MHz). In addition, Bayesil has specific requirements for sample
preparation and data collection that may be challenging to implement [96]. A comparison of Bayesil
and Batman indicated that both methods were useful for quantitative measurements, but required
expertise, manual intervention, and extensive computation time [97]. Capabilities available in Batman,
namely the ability to add new metabolite reference spectra and the ability to manually adjust a standard
metabolite’s spectrum to match the target spectrum, are an advantage over purely automated techniques,
such as Bayesil [97,99]. Alternatively, a clear advantage of Bayesil is the minimal computational time
and direct readout of concentrations for detected metabolites [96]. Overall, the ready availability of
software to automate metabolite quantitation presents a serious risk of over simplifying a complex
data analysis and the proliferation of erroneous interpretation [25].
Recent implementations of automated metabolite deconvolution algorithms have focused on
high-throughput analysis of NMR metabolomics data [100–102]. The automated quantification
algorithm (AQuA) was developed to limit the computational time by reducing the amount of NMR
spectral data used to quantify metabolites [100]. AQuA simplifies the deconvolution process by using
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only one unique 1H signal, instead of the metabolite’s entire NMR spectrum. Quantitation is then






where m is the matrix of the single per-metabolite reference signals,
→
x is the vector of peak intensities
from the experimental spectrum corresponding to chemical shifts in m, and
→
y is the resulting metabolite
concentrations. Ration analysis NMR spectroscopy (RANSY), on the other hand, identifies metabolites
on the basis of peak height ratios [103]. RANSY exploits the fact that all peak intensities from a given
metabolite are proportional to the number of magnetically nonequivalent spins such that peak ratios
are fixed and equivalent across spectra. Thus, across a relatively large dataset of NMR spectra (n = 100),
the coefficient of variation (CV) of peak ratios from the same metabolite should be theoretically zero
compared to the peak ratios between different metabolites given variable concentrations. Like Batman
and Bayesil, another method of metabolite deconvolution, ASICS (Automatic Statistical Identification
in Complex Spectra), utilizes a library of known metabolite 1D 1H-NMR spectra and matches reference
peaks to the experimental 1D 1H-NMR spectrum [102]. ASICS accomplishes this with a statistical
lasso-type estimator. Again, ASICS assumes the NMR spectrum of the complex mixture is a combination
of the warped spectra from the library: ∑
1≤i≤p
αi fi ◦φi + ε (2)
where p is the metabolite library size, αi is the effective metabolite concentration, f i is the NMR
spectrum, φi is a warping function to account for chemical shift changes, and ε is an error term.
ASICS was shown to outperform open source (e.g., Batman and Bayesil) and commercial software
(e.g., Chenomx) in terms of accuracy, as well as an improvement in computational time compared to
Batman and Bayesil [102]. However, ASICS, like many automated tools, struggles to accurately assign
metabolites in areas of overcrowding and is limited by the number of reference spectral available for
comparison [102]. Thus, there is still a need for robust methods to deconvolute 1D 1H-NMR spectra
and achieve accurate and complete metabolite quantification. Overall, current automated systems
lack flexibility to define experimental parameters, while semi-automated systems require expertise to
operate and implement effectively.
2.2. Applications in 1D qNMR Metabolomics
2.2.1. Alternative Nuclei as a Tool for Quantification
One of the many advantages of NMR spectroscopy is the ability to identify and quantify
compounds using multiple nuclei. In principle, it is possible to detect any magnetically active nuclei
by qNMR. The most common nuclei used in qNMR are those that have the highest sensitivity and
natural abundance (1H (99.9885%), 31P (100%)) and those that have a large chemical shift dispersion
(13C (220 ppm), 19F (800 ppm)). 1H, 13C, 15N, and 31P are also commonly utilized in metabolomics due
to their high occurrence in metabolites and biomolecules, where 1D 1H NMR is the popular choice.
Simply, qNMR experimental parameters are well-established for the acquisition of 1H-NMR spectra,
and minimal sample preparation or manipulation are required for using 1H-NMR in an untargeted
metabolomics study. Recent advances in method development and the optimization of experimental
parameters have enabled the application of 13C, 15N and 31P-NMR spectra for metabolomics and
qNMR [104–107]. 13C-NMR spectroscopy benefits from a broader chemical shift dispersion range but
is challenged by a low natural abundance (1.1%). Thus, metabolomics studies utilizing 13C NMR
commonly incorporate 13C-carbons by providing the organism or system a 13C-labeled nutrient or
metabolite. For example, human urine samples were treated with isotopically labeled 1,1′-13C2 acetic
anhydride to acquire a direct detected 1D 13C-NMR spectrum (Figure 4C) [108]. The addition of
1,1′-13C2 acetic anhydride caused the acetylation of all amines and the incorporation of a 13C label
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into select metabolites. This chemoselective tagging resulted in the identification and quantification of
amino acids present in human urine, while eliminating peak overlap common in 1H metabolomics
studies. Alternatively, NMR experiments of biofluids where 13C incorporation is not feasible need
to account for the low natural abundance of 13C by extensive signal averaging and by using highly
concentrated samples, high magnetic fields, cryoprobes, and/or submicroprobes.
15N-NMR is also characterized by a broad chemical shift dispersion of approximately 900 ppm.
However, the small gyromagnetic ratio, the long relaxation times, and the low natural abundance
of 15N (0.37%) have limited its application to qNMR and metabolomics. Accordingly, 15N-NMR has
been primarily used in qNMR as a resonance in a 2D NMR experiment [106]. Conversely, 31P-NMR is
100% abundant, with a high gyromagnetic ratio and a moderate chemical shift range of approximately
30 ppm. In fact, 31P-NMR saw extensive early usage in metabolomics analysis [109], but has been
underutilized of late, potentially because of unfounded concerns regarding chemical shift anisotropy
(CSA) effects [110]. While phosphorous-containing metabolites are not as numerous as other nuclei,
31P-NMR metabolomics is important to energy metabolism and cell signaling [107]. Energy-related
metabolites, such as ATP, ADP, and AMP, can be characterized by 31P-NMR (Figure 4D). For example,
1H and 31P-NMR was used to characterize brain metabolic changes in a rat model of chronic liver disease
that resulted in the induction of hepatic encephalopathy [111]. Perturbations in energy metabolism
was observed at the end stage of the disease. Specifically, 31P-NMR showed decreases in both ATP and
ADP 8 weeks post bile duct ligation. In essence, qNMR is not limited to 1H-NMR and the choice of
nuclei should be based on the specific needs of a given metabolomics investigation.
Hyperpolarization methods have also been applied to other nuclei besides 1H [112]. Similar to
PHIP, the parahydrogen-based NMR hyperpolarization method, SABRE-Relay (signal amplification by
reversible exchange-relay), has demonstrated quantification of low-concentration metabolites with
low-abundant nuclei through polarization transfer from parahydrogen [113–115]. This technique
has been shown to enhance the signal of natural abundant isotopes such as 13C (~1.1%) and 15N
(~0.37%) by a factor of 250 or 39,200, respectively. In this regard, SABRE-Relay allows for collecting
a naturally abundant 1D 13C or 15N spectrum of a millimolar sample with a single scan (Figure 4E).
SABRE has also been shown to enhance 31P (100%) signals by a factor of 8 [116]. The parahydrogen
hyperpolarization technique demonstrated the ability of NMR to exceed inherent limitations of
sensitivity and measure metabolites using low abundant nuclei. It should be noted that the detection
of naturally abundant nuclei (13C and 15N) with SABRE-Relay was targeted to nucleobases, peptides,
or proteins in high concentration samples. Millimolar concentrations were required for 15N detection.
Further optimization is required to make SABRE-Relay or other hyperpolarization methods amenable
for high-throughput metabolomics analysis of biomedical samples. Instead, isotope labeling and
natural abundance quantification are viable alternatives for targeted and untargeted metabolomics
investigations using traditional 1D NMR experiments.
2.2.2. Quantification by Solid State NMR Spectroscopy
Metabolite quantification by NMR is not limited to the solution state. Recent advances in magic
angle spinning magnetic resonance spectroscopy (MAS MRS) have improved metabolite quantification
in the solid state. In the solution state, dipolar coupling and the effect of CSA, the orientation dependency
of the chemical shift, are negligible due to high molecular mobility and the random tumbling and
reorientation of molecules in solution. The only effects measured in solution are the isotopic chemical
shift and the through bond coupling that give rise to the appearance of a traditional 1D 1H-NMR
spectrum. Conversely, in the solid state, molecular mobility is greatly restricted, and individual
molecule orientation to the external magnetic field (Bo) is relatively fixed. Thus, in the solid state MAS
MRS analysis, such as a tissue sample, dipolar coupling and CSA do not average to zero, which results
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in poorly resolved spectra with significant peak broadening [15]. The magnitude of the dipolar constant
(D) is defined as:
D = d
(








where (θ) is the angle between Bo and the internuclear distance (rIS) between spins I and S, γ is
the gyromagnetic ratio for spins I and S, h̄ = h/2π is Planck’s constant, and µ0 is the permeability
of a vacuum. Spectral broadening is also caused by local magnetic field gradients caused by the
tissue sample [117]. In MAS MRS, the solid sample is rapidly rotated at the magic angle (θ) of 54.7◦
(Figure 5A), where dipolar coupling and CSA are averaged to zero, in order to obtain a high-resolution
solid state NMR spectrum [118].
Similar to solution state NMR experiments, quantification by MAS MRS requires reference
standards. Fortunately, popular internal references (e.g., TSP and DSS) utilized in solution qNMR are
also amenable to solid state qNMR [16,119]. However, the same limitations with internal references
are encountered in the solid state. TSP and DSS are still prone to bind macromolecules, which includes
proteins and lipids that are prevalent in tissue samples. A further loss of the internal standard may
occur during MAS MRS sample preparation and rotor assembly, which may lead to an overestimation
of metabolite concentrations [119]. Glioblastoma multiforme tumor samples were used to compare
the relative performance of an internal standard (e.g., DSS) with the ERETIC method for a MAS
MRS qNMR study [119]. DSS-derived metabolite concentrations were consistently higher than the
ERETIC measurements. Furthermore, metabolite concentrations had a larger standard deviation
when measured by referencing DSS. For example, lactate concentrations were measured as 28.0 ± 9.1
and 50.8 ± 18.9 mmol/kg using the ERETIC method and the DDS internal standard, respectively.
Overall, DSS resulted in an overestimation of concentrations by an average of 170%. Similarly, in a
study of prostate surgical tissue samples analyzed by MAS MRS and solution state NMR, TSP levels
were found to be significantly reduced (71.3% reduction in TSP) when measured by MAS MRS [120].
This discrepancy in TSP levels would thus result in the overestimation of metabolites by MAS MRS.
Water resonance has also been utilized as an internal standard in MAS MRS experiments [121];
however, water content is likely to vary between tissues with heavy fat content, such as breast tissues
from cancer patients, and thus, can be an inconsistent reference for MAS MRS samples. External
standards have also been utilized in MAS MRS as a method of metabolite quantification [122]. As in
solution state NMR, ERETIC has demonstrated advantages in MAS MRS applications over traditional
internal and external reference standards [16,119,123]. ERECTIC has been successfully used to quantify
lactate in living human prostate biopsies cultured with [1,6-13C2]glucose (Figure 5B) [123]. Glycolysis
and TCA metabolites (e.g., lactate and glutamate) were quantified in tissue samples relative to the
calibrated amplitude of the ERETIC signal and then further standardized to the wet tissue weight of
the sample. Extracellular lactate accumulation was also quantified by TSP with solution state NMR.
One potential issue with MAS MRS quantification is the dependence on tissue weight for metabolite
quantification. An underlying assumption of this method is a consistent metabolite level throughout the
tissue. Some tissues, such as liver biopsies, have demonstrated a uniformity in metabolite composition
throughout the tissue sample, while others, such as tumors, are particularly susceptible to a larger
variance in metabolite concentration [124]. For example, a study of intratumoral heterogeneity in
breast cancer tissues demonstrated a non-uniform metabolome [124]. Multiple samples were taken
from the same tumor which showed significant differences in metabolite quantification across the
replicate samples. Specifically, the standard deviation in metabolite concentrations from the breast
cancer tissue varied from 0.48 to 0.74 µmol/g. The metabolite concentration variance was significantly
higher compared to the standard deviation range of 0.12 to 0.20 µmol/g observed for murine liver
tissue samples. It should be noted that while metabolite concentrations varied significantly between
biological replicates, this did not limit the ability to predict breast cancer sample identity through
Random Forest analysis [124]. A similar concern regarding the spatial variability of metabolites exists
with the solution state NMR analysis of tissues. The solvent extraction of a homogenized tissue sample
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will only provide an overall average of metabolite concentrations. Any spatial variance due to the
intrinsic heterogeneity of the tissue structure will be lost. Special attention must be taken to properly
quantify metabolites from heterogeneous tissues. Overall, a significant number of 1H MAS MRS
studies have been conducted to identify and quantify metabolites relevant to various cancers. For a
detailed description of the application of 1H MAS MRS to metabolite quantification, please see the
reviews by Moestue et al. 2011 [125] and Gogiashvili et al. 2019 [126].
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2.2.3. Multiplatform Approach to 1D Metabolite Quantification
In general, a multi-omics approach combines genomics, proteomics, metabolomics, and/or lipidomics
in order to achieve a thorough characterization of a system [127,128]. Similarly, a multiplatform approach
intends to combine multiple analytical techniques to extend cover of the metabolome [129]. Recent advances
in multiplatform technologies have demonstrated the combined strength of liquid chromatography/gas
chromatography–mass spectrometry (LC/GC–MS) and NMR in the identification and quantification of
metabolites. Simply, a multiplatform approach takes advantage of the ease of NMR quantification and the
sensitivity of LC/GC–MS. For example, 2D 1H-13C HSQC NMR was combined with GC–MS to characterize
the metabolome of Chlamydomonas reinhardtii following treatment with two lipid accumulation modulators
(WD30030 and WD10784) [130,131]. In this case, approximately one-third of the metabolites of interest
were uniquely identified by NMR, one-third by GC–MS, and one-third by both techniques. Importantly,
the metabolites identified by both NMR and GC–MS exhibited a similar response to compound treatment.
NMR and MS were shown to be complementary techniques that together achieved a broader coverage of
the metabolome and the complete characterization of the metabolic response to a compound treatment that
was not possible by either method alone (Figure 6A) [130]. qNMR has also been shown to guide the absolute
quantification of metabolites from blood samples using MS [132]. Simply, qNMR was used to quantify
30 metabolites from an arbitrarily identified reference sample from the sample set. The corresponding
multiple-reaction monitoring (MRM) peak integral from the mass spectrum of the same reference sample





where C(MS)mn is the absolute concentration of metabolite m in sample n based on the MS spectrum,
MRMmn is the MS peak area in the reference sample r and MRMmn is the MS peak area in sample n for
metabolite m, and C(NMR)mr is the absolute concentration of metabolite m as determined from the NMR
spectrum of reference sample r. Unfortunately, the qNMR–MS method is still negatively impacted
by matrix effects, which may explain a poor correlation between MS- and NMR-derived absolute
concentrations for a subset of metabolites. To address this issue, the qNMR–MS method was refined
to include derivatization with and without an isotope-labeled reagent (Figure 6B) [133]. As before,
qNMR was used to define the absolute quantitation of metabolites in a reference sample and MS was
used to determine the corresponding reference MS peak integral. The reference sample was then
derivatized with an isotope labeled reagent, while all other samples in the dataset were derivatized
with the same unlabeled reagent. An aliquot of the derivatized reference sample was added to each
sample in the test set prior to collecting a mass spectrum. A response factor (R) was measured for each
metabolite based on a ratio of the peak areas for the labeled and unlabeled MS peaks, which was then








where AR–labeled and AR–unlabeled are the MS peak areas after derivatization with a labeled and unlabeled
reagent, respectively; Csi and CR are the metabolite’s concentrations in the test sample and reference
sample, respectively; Asi and ARi-labed are the metabolite’s peak areas in the unlabeled test sample and
the labeled reference sample, respectively. A qNMR-guided LC–MS/MS study was able to determine
the absolute quantification of four immunosuppressive drugs in human whole blood [134]. The four
drugs, cyclosporine A, tacrolimus, sirolimus, and everolimus, were detected over a concentration
range of 0.25 to 50 ng/mL with an overall uncertainty of ≤9.0%. Importantly, the four drugs were
detected and quantified in under 10 min, while eliminating calibration curves typically required by MS
quantification. Furthermore, avoiding the need for a calibration curve is particularly beneficial and
may eliminate a practical barrier since numerous metabolites are not commercially available or may be
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cost-prohibitive to obtain. Several recent studies have utilized a combined NMR and MS platform to
identify and quantify biomarkers for neurodegeneration [20], bipolar disorder [135], autism spectrum
disorder [136], and prostate cancer [137], among others. The combination of NMR and MS improves
the limits of detection, the ease and speed of quantification, and ultimately, expands the coverage of
the metabolome beyond the capabilities of either technique alone.Molecules 2020, 25, x 19 of 32 
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3. Metabolite Quantification in 2D NMR Metabolomics
In addition to 1D NMR, multidimensional NMR offers a robust toolbox of qualitative and
quantitative methods to detect and quantify metabolites using homonuclear and heteronuclear
chemical shifts, spin–spin couplings (J-coupling), dipolar couplings, and through space dipolar–dipolar
interactions (NOEs) [8,138]. As outlined in Figure 7A [139], quantitative metabolomics of a complex
mixture involves: (1) metabolite identification by 2D NMR analysis, (2) acquisition of reference
standards, (3) collection of reference 2D NMR spectra, and (4) quantification of metabolites according
to known reference concentrations. As shown in Figure 7B, a major advantage of 2D NMR experiments
is the ability to disperse peaks into two-dimensional space and to significantly increase spectral
resolution. Essentially, a 2D NMR experiment may be viewed as a simple deconvolution of a 1D
NMR spectrum. Furthermore, 2D pulse sequences that exploit J-coupling, dipolar coupling, and/or
NOEs to correlate multiple chemical shifts to the same compound provide a means to unambiguously
assign known metabolites from complex biofluids. As a non-destructive technique, NMR enables the
acquisition of multiple experiments for the qualitative and quantitative characteristics of biological
samples. Thus, a combination of multiple 2D NMR experiments have been commonly employed to
identify the structure of unknown or novel metabolites [140].
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traditional metabolomics (left) and the four-step 2D quantitative metabolomics protocol fast metabolite
quantification (FMQ) by NMR. (B) depicts (top) 1D 1H-NMR spectrum of equimolar mixture of
small-molecule standards and (bottom) 2D 1H-13C HSQC NMR spectra of the same standard mixture
(red) overlaid on a spectrum of Arabidopsis thaliana (blue). Reprinted with permission from Lewis, I. A.;
Schommer, S. C.; Hodis, B.; Robb, K. A.; Tonelli, M.; Westler, W. M.; Sussman, M. R.; Markley,
J. L., Method for Determining Molar Concentrations of Metabolites in Complex Solutio s fr m
Two-Dimensional 1H-13C-NMR Spectra. Analytical Chemistry 2007, 79, 9385–9390. Copyright 2007
American Chemical Society.
One limitation of 2D NMR experiments is the significant increase in experimental time going from
1D NMR experiments (minutes) to 2D NMR experiments (hours to days), which may be a practical
limitation for qNMR studies involving large sample sizes (n > 100). Advances in non-uniform sampling
(NUS) are commonly utilized to increase sensitivity, while keeping a constant acquisition time [141,142].
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NUS is commonly employed for 2D NMR experiments with conservative 50% data sparsity for
metabolomics experiments [143]. Furthermore, a sine-weighted Poisson-gap sampling scheme with
the Iterative Soft Thresholding Compressed Sensing method (CS-IST) reconstruction algorithm yielded
the best qNMR performance. Specifically, an average CV of 8.03 was obtained for six metabolites
over a concentration range from 15.6 to 500 µM [143]. The accuracy and precision of the qNMR
experiments were observed to be acceptable according to FDA guidelines. Overall, the application of
NUS to metabolomics samples is challenged by the complexity of the samples (i.e., upwards of a 100 or
more metabolites), and the diversity of relaxation parameters (i.e., T1 and T2) across the metabolites.
Accordingly, it may be difficult to identify a single set of NUS experimental parameters to accurately
quantify all metabolites in a sample. Thus, a conservative approach to employing NUS is recommended.
Furthermore, advances in experimental design, NMR pulse sequences, and instrumentation have
also shortened the acquisition time for 2D NMR experiments while also improving the limits of
metabolite quantification.
3.1. Experimental Parameters and Pulse Sequences for Metabolite Quantification by 2D NMR
A variety of 2D NMR experiments have been applied to metabolomics. Common heteronuclear
experiments include the heteronuclear (13C/15N) single quantum coherence (HSQC) experiment that
correlates a 1H chemical shift with its directly bonded 15N-nitrogen or 13C-carbon chemical shift
(1H-13C, Figure 7B, or 1H-15N) [18,139], and the heteronuclear multiple bond correlation (HMBC)
experiment that correlates a 1H chemical shift with 13C chemical shifts that are two and three bonds
away [144]. HSQC and HMBC experiments are particularly useful in metabolomics because the signal
of the lower sensitive heteronuclei (i.e., 13C and 15N) is enhanced through nuclear spin polarization
from the more sensitive active nuclei (1H) through J-coupling. In this regard, chemical shifts of low,
naturally abundant 13C and 15N nuclei are easily and quickly obtained, and directly correlated to 1H
chemical shifts. In addition, the large chemical shift range of the heteronuclei (>200 ppm) help disperse
the overlapped 1H chemical shifts. The HMBC experiment is essentially a companion experiment to the
HSQC experiment and highlights long range couplings to reveal detailed structural information about
the metabolites. Altogether, the combination of an HSQC and HMBC experiment has the potential of
providing the complete spin system (i.e., all 1H, 13C, and 15N chemical shifts) for the unambiguous
identification of metabolites.
Many metabolomic studies also utilize 2D 1H-13C HSQC as a tool for metabolite quantification.
Typically, HSQC experiments are used to determine only relative metabolite changes because
quantification is not as straight forward as 1D NMR experiments. While HSQC peak heights or
area are still proportional to metabolite concentrations, they are also modulated by other factors such
as differences in coupling constants, relaxation times, and experimental parameters. One potential
solution is the fast metabolite quantification by NMR (FMQ) approach. FMQ used a combination
of standard reference calibration curves with a non-uniform sampling scheme to decrease sample
collection time of 2D NMR experiments [139]. Critically, the reference samples and 2D 1H-13C HSQC
spectra were prepared and collected under essentially identical conditions. The HSQC spectra were
collected with a range of metabolite concentrations (2 to 10 mM) and the HSQC peak intensities were
plotted as a function of concentration and then, normalized to an internal standard to produce a
calibration curve. Approximately 40 metabolites from extracts of Arabidopsis thaliana, Saccharomyces
cerevisiae, and Medicago sativa were quantified with an accuracy error of 2.7%.
HSQC0 is an alternative approach that addresses the HSQC quantitation problem while avoiding
the need for standard calibration curves. HSQC0 collects a series of HSQC spectra with an increasing
repetition time of the basic HSQC block [145,146]. Each HSQC peak volume is then plotted as a function
of the number of HSQC blocks (usually 1 to 3), and then, a best-fit line is extrapolated to time-zero to
determine the “true” peak volume. In a similar manner to 1D qNMR, an absolute concentration is
obtained by comparing the time-zero peak volumes to an internal standard. Alternatively, a 2D modified
ERETIC avoids the need to include an internal reference for calibrating an HSQC experiment [147].
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It should be noted that the HSQC0 pulse sequence requires a collection time of 8 h for each of the
three HSQC spectra (blocks). A total acquisition time of 24 h may limit the utility of HSQC0 for
high-throughput qNMR. The HSQC0 acquisition time was reduced to 3 h per spectrum with the use of
a relaxation enhancing agent (e.g., Fe(III)EDTA)) for the analysis of bovine liver extracts [145].
The Q-HSQC [148] and other variants (QQ-HSQC, Q-CAHSQC, Q-OCCAHSQC, etc.) [149–151]
have addressed the HSQC quantitation issue by replacing a single average value for the one bond
1H-13C coupling constant with an effective range of coupling constants. This is accomplished by
summing signals from a collection of experiments with different values (in a 3:1 ratio of 2.94:5.92 ms)
for the INEPT delay (i.e., ∆= 1/2J). This results in a flat, uniform transfer efficiency instead of a peak at
150 Hz (∆ = 3.33 ms), which is the typical average coupling constant and setting used for a 2D 1H-13C
HSQC experiment. As a result, the Q-HSQC acquisition time is four time longer than a standard HSQC
experiment [148]. The total reported acquisition time ranged from 12 to 30 h for a model mixture of
lignins. The subsequent Q-CAHSQC and Q-OCCAHSQC experiments required a total experimental
time of 16 h and 5 min or 15 h and 57 min to measure strychnine, respectively [150,151]. The Quick,
Quantitative HSQC (QQ-HSQC) pulse sequence was developed to solve this long acquisition time.
The QQ-HSQC pulse sequence utilizes a slice-selective adiabatic sweep to pulse three-fourths of the
active region with the shorter delay (∆ = 2.94 ms), while the other fourth was exposed to the longer
delay (∆ = 5.92 ms). This sweep pulse preserved the 3:1 ratio necessary for quantification while
reducing the acquisition time to 45 min for a sample of strychnine [149]. It should be noted that the
Q-HSQC experiments also lead to an overall decrease in transfer efficiency (~30% lost) and spectral
sensitivity. Overall, the Q-HSQC and its sequence variations (QQ-HSQC and Q-CAHSQC) deliver a
standard deviation of 7 to 9% from expected results [149].
The perfect HSQC pulse sequence replaces that standard INEPT block with a perfect echo INEPT
module that suppresses phase distortions due to 1H-1H J-coupling, leading to further improvements
in quantitation [152]. Of course, completely suppressing 1H-1H J-coupling in an HSQC spectrum
would lead to further overall improvement in spectral quality, sensitivity, and ease of quantitation.
The quantitative perfected and pure shifted HSQC (QUIPU HSQC) combines a number of recent
advances to speed up 2D data acquisition (e.g., NUS, spectral aliasing, and variable repetition time) with
a pure shift (i.e., homo-decoupled spectrum) to improve the quantitation of the HSQC experiment [153].
QUIPU HSQC achieved a 6 to 9 factor improvement in data acquisition, a higher quality spectrum due
to the removal of 1H-1H J-coupling, an average trueness of 8%, and a repeatability of 6%. The QUIPU
HSQC spectrum, however, still required 5 h to acquire, which would be a challenging limitation for
large datasets.
The potential of in vivo metabolite quantification by 2D 1H-13C HSQC was evaluated with 13C
isotopically enriched Daphnia magna (water fleas) [154]. In this study, the 2D modified ERETIC
was combined with the perfect HSQC sequence or the Q-OCCAHSQC sequence to quantify the
in vivo concentrations of alanine and phenylalanine. While both pulse sequences yielded comparable
quantitation on standard samples, with average root-mean-square deviations (RMSDs) of 4.5 to 6.2%,
sample heating and TOCSY artifacts were identified problems with Q-OCCAHSQC. It was also observed
that the OC decoupling pulse outperformed standard GARP-4 and CHIRP-95 decoupling pulses with
improved bandwidth, no apparent artifacts, and better reproducibility in signal quantification. For the
water fleas in vivo samples, the perfect HSQC pulse sequence with optimized parameters yielded
RMSDs of 6.0% (alanine) and 2.9% (phenylalanine) compared to 1D qNMR data.
In addition to heteronuclear NMR spectroscopy, homonuclear NMR spectroscopy has also been
utilized for metabolite identification and quantification. Common 2D homonuclear experiments used
in qNMR include the correlation spectroscopy (COSY) experiment that correlates J-coupled (typically
three-bonds) 1H chemical shifts [155], the total correlation spectroscopy (TOCSY) that correlates all
J-coupled 1H chemical shifts in a spin system [71,107], and 2D NOESY experiments that correlate all
1H chemical shifts that are dipolar-coupled through space (≤6 Å) [156]. Similar to the HSQC and
HMBC spectral pair, the COSY and TOCSY experiments provide complementary information with the
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potential of obtaining the complete 1H spin system for the unambiguous identification of metabolites.
An advantage of COSY and TOCSY experiments to qNMR is the intrinsically higher sensitivity of
1H NMR relative to other nuclei. Unfortunately, the absolute quantification of metabolites from a
COSY or TOCSY spectrum encounters similar challenges with accuracy as occurred with an HSQC
spectrum. Again, peak intensities are modulated by differences in coupling constants, relaxation times,
and experimental parameters. Furthermore, the integration of COSY and TOCSY cross-peaks may
be complicated by complex splitting patterns with multiple antiphase (opposite intensities) peaks
separated by the coupling constant. Additionally, this cross-peak shape complexity increases the
likelihood of peak overlap and partial peak cancellation. Long experimental times, relative to 1D
qNMR, are also a concern with COSY and TOCSY experiments.
A “multi-scan single shot” (M3S) strategy demonstrated a quantitative improvement over a
traditional COSY experiment, while decreasing experimental time [157]. The MS3 strategy uses
ultrafast NMR techniques that obtain a 2D NMR spectrum with a single scan by employing a spatially
encoded pulse sequence [158]. M3S improves quantitation by collecting the single scan COSY spectrum
with 256 scans, for a total experimental time of 20 min. The M3S COSY spectrum was shown to be more
sensitive compared to a traditional COSY experiment due to the suppression of t1 noise. The M3S COSY
was compared to the traditional COSY experiment by quantifying 14 metabolites. Quantification was
achieved by using the standard addition method with an added concentration range of 1.0 to 3.7 mM.
Simply, a standard sample consisting of the 14 metabolites at a known concentration was added to the
breast cancer cell extract and the COSY spectrum was then re-acquired. The process was repeated three
times, the peak volumes were plotted as a function of the added metabolite concentrations, and then,
a standard addition curve was fitted (V = a[m] + b) to the data to solve the metabolite concentrations
([m]). The M3S COSY achieved a precision error of 1 to 4% compared to 5 to 18% for the traditional
COSY experiment. The M3S COSY also had better linearity.
In addition to a COSY analysis, 1H-1H TOCSY and 1H −13C HSQC-TOCSY experiments have
also been utilized to identify biomarkers in complex mixtures [159,160]. As previously demonstrated
with heteronuclear NMR experiments, the primary motivation of homonuclear NMR experiments
has been the identification of metabolites. The 1H(13C)-TOCCATA database is a repository of 1H
and 13C chemical shift information and spin systems for 455 metabolites, which is widely available
for the metabolomic assignment of biomarkers [161]. While quantification of metabolites by 2D
analysis has been demonstrated, absolute metabolite quantification has seen limited usage compared
to relative quantification.
3.2. Software for Quantification of 2D NMR Data: Status and Limitations
Software development for the analysis of 2D NMR metabolomics data has predominantly focused
on assignment and deconvolution strategies. Open source data repositories, such as HMDB [91]
and BMRB [92], have assembled and curated multiple 2D NMR spectral data for over a thousand
known metabolites. HMDB reports the accumulation of 1040 heteronuclear NMR spectra. These
databases enable manual, semi-automated, and automated assignments, and are essential resources
for software such as COLMARm (CCIC, www.spin.ccic.ohio-state.edu). COLMARm makes use of
chemical shifts from 1H-13C HSQC, 1H-1H TOCSY, and 1H-13C HSQC-TOCSY spectra to automate
metabolite assignments [162]. Other software such as MetaboMiner (MetaboMiner, www.wishart.
biology.ualberta.ca/metabominer) [163] and Spin Assign (RIKEN, www.dmar.riken.jp/spinassign/) [94]
are also available for semi-automated metabolite assignments. While several software applications
have been developed for metabolite identification, there are fewer software available for metabolite
quantification. Several studies have utilized statistical models based on external standard calculations
to quantify metabolites [139,154,157] or peak integration of successive experiments [153]. In addition,
software within the virtual machine NMRbox (National Center for Biomolecular NMR Data Processing
and Analysis, https://nmrbox.org/) [164] has been utilized for relative quantification of 2D NMR
metabolomics experiments [20,106,107]. It is evident that while the identification of metabolites by 2D
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NMR has expanded rapidly in recent years, the development of universally applied quantification
methods remain elusive.
4. Final Thoughts and Conclusions
The high accuracy and reproducibility of metabolite quantitation and the ease and ready application
of qNMR methods makes NMR a unique resource for metabolomics. Metabolite quantification by
NMR has seen many advances in recent years, and NMR-based metabolomics continues to be adopted
by a variety of fields. While techniques such as LC–MS and GC–MS have dominated metabolomics
due to a superior sensitivity, NMR has significantly improved metabolite quantification through the
development of reference standards, pulse sequences, physical and chemical deconvolution methods,
hyperpolarization techniques, physical and chemical deconvolution methods, and the integration of
multiple analytical platforms.
ERETIC and common external and internal standards (e.g., TSP and DSS) have all been extensively
utilized in metabolomics quantification. Importantly, each method yielded acceptable accuracy and
precision for qNMR, but each approach also has unique advantages and limitations that must be
considered during experimental design. For example, the versatility of ERETIC has been shown to
benefit many NMR applications, but deconvolution software routinely relies on internal standards for
quantification. A number of computational methods for metabolite deconvolution and quantification
were discussed. While progress has been made, significant advancements are still needed. For example,
semi-automated metabolite assignment is now possible, but the refinement of the identification and
quantification of individual metabolites still requires manual intervention by an expert. Open source
libraries such as HMDB and BMRB have assembled reference spectra for thousands of metabolites
to facilitate accurate metabolite assignments, but the databases are far from complete, where only a
small fraction of the predicted or known metabolites have an entry, and each metabolite entry may not
have a complete set of standard NMR spectra. The spectral data may also be dispersed across multiple
databases. Instead, a single NMR metabolomics database that compiles all available reference spectra
with ongoing efforts to acquire missing spectral data would be a preferred alternative.
Simplification of the NMR spectrum may also improve metabolite identification and quantification.
The most common approach is to combine NMR with HPLC to isolate and quantify specific metabolites
of interest. Alternatively, removal of metabolites or chemical classes can be achieved by solvent
extraction, chemical modification, enzymatic degradation, or selective binding (e.g., nanoparticles).
Of course, the chemical or physical manipulation of a biofluid is likely to perturb the absolute
concentration of a given metabolite [165]. Alternatively, a variety of NMR experiments or approaches
may achieve comparable outcomes. The CPMG pulse sequence or diffusion-editing are routinely
employed to filter macromolecules from metabolites or lipids. However, metabolite binding to
the filtered macromolecules may lead to erroneous quantifications [42]. Multidimensional NMR
experiments may remove spectral overlap by spreading NMR signals into two or three dimensions,
but at the cost of longer experimental times and potentially lower sensitivity. The application of 13C,
15N, or 31P NMR can expand the resolution of 2D NMR experiments or greatly simplify a 1D NMR
spectrum by selecting for metabolites that only contain the specified heteronuclei. Similarly, a selective
or semi-selective TOCSY experiment may select a single spin system or metabolite from a complex
mixture to improve resolution [70,71], but these approaches may lead to lower sensitivity and an
increase in the limits of detection for the qNMR experiment. In all cases, the simplification of the
NMR spectra will greatly reduce the number of detected metabolites and may be more appropriate for
targeted metabolomics. Overall, the proper choice of a spectral simplification technique will depend
on the specifics needs of a given qNMR experiment.
qNMR is also challenged by the intrinsically low sensitivity of NMR spectroscopy and by
limitations in sample size. A number of recent instrumentation and methodology advancements
have resulted in significant improvements in NMR sensitivity. In addition to higher magnetic fields
(1.2 GHz) [73], cryoprobes combined with microprobe or submicroprobe technologies have also
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significantly improved sensitivity while reducing sample requirements to 30 µL. It is now feasible to
detect metabolites at submicromolar concentrations [77,78]. Further advancements in hyperpolarization
techniques, such as PHIP and SABRE-Relay, show great promise in enhancing NMR sensitivities
by multiple orders of magnitude [81,113–115]. Similarly, multiplatform approaches that combine
LC/GC–MS with NMR may enable metabolite quantification into the sub-nanogram regime [132].
However, requirements for additional specialized and expensive equipment may limit the broad
application or adoption of these techniques.
qNMR has also seen advancements in solid state methodology, improved utilization of nuclei
such as 13C, 15N, and 31P for multidimensional NMR, and the adoption of multiple analytical platforms
for the expanded coverage of the metabolome. The use of 13C or 15N-NMR routinely relies on
incorporating 13C-carbons or 15N-nitrogens into the biological samples, which is not usually an option
for biofluids. Nevertheless, significant advancements in hyperpolarization techniques are enabling the
detection of naturally abundant 13C and 15N nuclei. While 2D NMR metabolomics has not achieved the
same level of high-throughput analysis as 1D NMR, advancements in pulse sequences, NUS acquisition,
and applications, such as fast metabolite quantification by NMR, have enabled the inclusion of 2D
NMR experiments into metabolomics studies without sacrificing throughput or signal sensitivity.
Several 2D NMR pulse sequences have been developed to quantify metabolites through 1H-13C bond
correlation, including HSQC0 and many variations of the Q-HSQC approach. These techniques offer
an expanded toolkit for metabolite quantification by NMR while eliminating the extensive spectral
overlap that plagues 1D NMR. Overall, qNMR is a valuable and integral resource for metabolomics
and has benefited numerous applications from drug discovery and disease diagnosis to environmental
and nutritional studies.
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